These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9074523)

  • 21. [89Sr Therapy for pain relief in patients with bone metastases].
    Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
    Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nuclear medicine therapy of bone metastases].
    Kimmig B; Hermann HJ; Kober B
    Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strontium and samarium therapy for bone metastases from prostate carcinoma.
    Dickie GJ; Macfarlane D
    Australas Radiol; 1999 Nov; 43(4):476-9. PubMed ID: 10901963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose measurement for 89Sr chloride injection.
    Hung JC
    Health Phys; 1995 Apr; 68(4):571. PubMed ID: 7883570
    [No Abstract]   [Full Text] [Related]  

  • 26. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
    Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
    Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.
    Turner SL; Gruenewald S; Spry N; Gebski V;
    Br J Cancer; 2001 Feb; 84(3):297-302. PubMed ID: 11161391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Question of the month--January 1995. What is the optimal dose of 89Sr for bone pain palliation?
    Khader Z
    Nucl Med Commun; 1995 Apr; 16(4):306. PubMed ID: 7542759
    [No Abstract]   [Full Text] [Related]  

  • 30. Pain palliation with strontium-89 in children with metastatic disease.
    Charron M; Brown M; Rowland P; Mirro J
    Med Pediatr Oncol; 1996 Jun; 26(6):393-6. PubMed ID: 8614375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
    Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
    Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment].
    Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA
    Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)].
    Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M
    Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396
    [No Abstract]   [Full Text] [Related]  

  • 34. Hematologic depression following therapy with strontium-89 chloride.
    Cowan RJ; Chilton HM; Cooper MR; Ferree CR; Watson EE; Robinson RG
    Clin Nucl Med; 1986 Dec; 11(12):845-6. PubMed ID: 2434277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
    Dormia E; Mantovani F; Minervini S; Malagola G; Castellani R; Dormia G; Gonnella G; Mazza L; Luongo P; Bertana F
    Arch Ital Urol Androl; 1993 Apr; 65(2):161-6. PubMed ID: 8330061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
    Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
    Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
    Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
    [No Abstract]   [Full Text] [Related]  

  • 39. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of metastatic bone pain with strontium-89.
    Robinson RG; Spicer JA; Preston DF; Wegst AV; Martin NL
    Int J Rad Appl Instrum B; 1987; 14(3):219-22. PubMed ID: 3667305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.